Tag: trastuzumab
Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...
The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...
FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...
José Baselga, a Leading Cancer Researcher, Dies at 61
José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...
New Phase I Study Investigates [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing...
As part of a new study focusing on advanced targeting human epidermal growth factor receptor-2 (HER2-) expressing cancers, including locally advanced or metastatic solid...
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...
San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...
In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...
Daiichi Sankyo Accelerates BLA Submission for [Fam-] Trastuzumab Deruxtecan in HER2...
Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...
Orphan Drug Designation for Alteogen’s Antibody-Drug Conjugate for the Treatment of...
Alteogen, a Korea-based biopharmaceutical company focusing on the development and commercialization of novel anticancer drugs such as antibody-drug conjugates, has received an approval for...
DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...
DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...
Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response...
Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...
